Preferred Label : odevixibat;
UNII : 2W150K0UUC;
Origin ID : C000713258;
UMLS CUI : C5238052;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3586458/fr/kayfanda-odevixibat-traitement-du-prurit-cholestatique-associe-au-syndrome-d-alagille
2025
false
false
false
France
Odevixibat sesquihydrate (substance)
cholestatic pruritus in Alagille syndrome
Cholestatic pruritus (disorder)
infant
child
adult
administration, oral
treatment outcome
insurance, health, reimbursement
odevixibat
evaluation of the transparency committee
pruritus
odevixibat
alagille syndrome
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kayfanda
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
odevixibat
odevixibat
---
https://ansm.sante.fr/tableau-acces-derogatoire/bylvay
2024
false
false
false
France
French
insurance, health, reimbursement
odevixibat
odevixibat
summary of product characteristics
package leaflet
guidelines for drug use
infant
child
pruritus
cholestatic pruritus in Alagille syndrome
alagille syndrome
---
https://www.has-sante.fr/jcms/p_3500210/fr/bylvay-odevixibat-prurit-cholestatique-associe-au-syndrome-d-alagille
2024
false
false
false
France
cholestatic pruritus in Alagille syndrome
Cholestatic pruritus (disorder)
treatment outcome
insurance, health, reimbursement
child
infant
administration, oral
odevixibat
evaluation of the transparency committee
odevixibat
alagille syndrome
---
https://www.has-sante.fr/jcms/p_3427763/fr/bylvay-odevixibat-prurit-cholestatique-associe-au-syndrome-d-alagille
2023
false
false
false
France
cholestatic pruritus in Alagille syndrome
infant
child
guidelines for drug use
treatment outcome
insurance, health, reimbursement
administration, oral
odevixibat
evaluation of the transparency committee
pruritus
alagille syndrome
odevixibat
---
https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
odevixibat
odevixibat
drug approval
europe
odevixibat
infant
child
adult
Progressive Familial Intrahepatic Cholestasis
administration, oral
cholestasis, intrahepatic
drug monitoring
drug interactions
pregnancy
breast feeding
ileal sodium-dependent bile acid transporter
drug evaluation, preclinical
cholestasis, intrahepatic
cholestasis, progressive familial intrahepatic 1
cholestasis, progressive familial intrahepatic 2
sodium-bile acid cotransporter
benzodiazepines
butyrates
benzodiazepines
butyrates
symporters
organic anion transporters, Sodium-Dependent
---
https://www.has-sante.fr/jcms/p_3299696/fr/bylvay-odevixibat
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
odevixibat
odevixibat
administration, oral
cholestasis, intrahepatic
Progressive familial intrahepatic cholestasis type 1
cholestasis, progressive familial intrahepatic 1
cholestasis, progressive familial intrahepatic 2
infant
child
adolescent
adult
carrier proteins
odevixibat
evaluation of the transparency committee
---
